Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
47 participants
INTERVENTIONAL
2011-03-31
2015-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Renal Denervation in Treatment Resistant Hypertension
NCT01687725
Renal Denervation in Patients With Uncontrolled Hypertension in Chinese
NCT01390831
Renal Sympathetic Modification in Patients With Essential Hypertension
NCT01417221
Renal Sympathetic Denervation Combined With Aorticorenal Ganglion Ablation for Treatment of Hypertension
NCT06864962
Denervation of the REnal Artery in Metabolic Syndrome
NCT01465724
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Group 1
Group 1 received ablation from distal to ostial of bilateral renal arteries
Thermocool®Rcatheter
The full length RDN was performed discretely from distal to proximal by point to point using Thermocool®Rcatheter
Group 2
group 2 received ablation at proximal of bilateral renal arteries
Thermocool®Rcatheter
The proximity renal denervation was performed discretely at 10-15 mm of proximal renal artery, using Thermocool®Rcatheter
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Thermocool®Rcatheter
The full length RDN was performed discretely from distal to proximal by point to point using Thermocool®Rcatheter
Thermocool®Rcatheter
The proximity renal denervation was performed discretely at 10-15 mm of proximal renal artery, using Thermocool®Rcatheter
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* patients had to be on a stable drug regimen of at least 3 antihypertensive medications with no changes for 1 month before enrollment.
* Despite being treated with at least three antihypertensive drugs(including one diuretic), or confirmed intolerance to medications;
* ≥ 18 years old,;
* did not have any known secondary cause of hypertension;
* had a glomerular filtration rate estimated with the modification of diet in renal disease formula, of 45 ml/min/1.73m2 or more.
Exclusion Criteria
* implanted pacemakers or implantable cardioverter defibrillators;
* pregnant women;
* haemodynamically significant valvular disease;
* patients with renovascular abnormalities(including mild to severe renal artery stenosis, especially caused by atherosclerosis, previous renal stenting or angioplasty, or known dual renal arteries, or diameter of renal artery identified by angiography less than 4 mm and/or length of renal artery less than 2 cm)
18 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
The Second Affiliated Hospital of Chongqing Medical University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Yuehui Yin
Director and Professor, Dept. of Cardiology, the second affiliated hospital of Chongqing Medical University, Chongqing Cardiac arrhythmias service center
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
2ndChongqingMU
Chongqing, Chongqing Municipality, China
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
SWAN- RDN Strategy
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.